← Back to Search

Neuraminidase Inhibitor

Oseltamivir for Thrombocytopenic Purpura

Phase 3
Waitlist Available
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 and day 14
Awards & highlights

Summary

This trial is testing oseltamivir, a flu medication, to see if it can help adults with a condition that affects blood platelets. Oseltamivir is commonly used to reduce the duration of flu symptoms. The goal is to find out if oseltamivir can improve platelet function with fewer side effects than current treatments. If successful, this could lead to better long-term health outcomes for these patients.

Eligible Conditions
  • Thrombocytopenic Purpura

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean platelet glycoprotein sialyation
Secondary study objectives
Anti-platelet glycoprotein antibody specificity/titer
Cytokine profiles
Effects of antibodies on macrophage- and hepatocyte-mediated Fc-dependent and independent phagocytosis in vitro
+8 more

Side effects data

From 2018 Phase 4 trial • 184 Patients • NCT01850446
2%
Dysgeusia
1%
Nausea
1%
Photophobia
1%
Flatulence
1%
Chest pain
1%
Paraesthesia
1%
Insomnia
1%
Hyperthermia
1%
Oropharyngeal pain
1%
Bronchitis
1%
Pruritus
1%
Autonomic nervous system imbalance
1%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ergoferon (1 Tablet 3 Times a Day)
Oseltamivir (Tamiflu) - 1 Capsule (75mg) Two Times a Day

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: OseltamivirExperimental Treatment1 Intervention
Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsule administered orally twice daily for five consecutive days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oseltamivir
FDA approved

Find a Location

Who is running the clinical trial?

Unity Health TorontoLead Sponsor
554 Previous Clinical Trials
454,261 Total Patients Enrolled
Li Ka Shing Knowledge InstituteUNKNOWN
2 Previous Clinical Trials
999 Total Patients Enrolled
University of TorontoOTHER
705 Previous Clinical Trials
1,021,521 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top